<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Oncology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CE97FC1C-8B83-431B-8DE7-749A3C4A5F95"><gtr:id>CE97FC1C-8B83-431B-8DE7-749A3C4A5F95</gtr:id><gtr:firstName>Bart</gtr:firstName><gtr:surname>Vanhaesebroeck</gtr:surname><gtr:orcidId>0000-0002-7074-3673</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ED6656DB-69F1-48A2-81F5-4648B494FFCB"><gtr:id>ED6656DB-69F1-48A2-81F5-4648B494FFCB</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>K</gtr:otherNames><gtr:surname>Semple</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/00A91100-6B82-4AF6-9FED-87714B19DAAF"><gtr:id>00A91100-6B82-4AF6-9FED-87714B19DAAF</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Angell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FM013278%2F1"><gtr:id>E653385A-1CAF-4B0C-9495-3C1C2E8C18BC</gtr:id><gtr:title>Validation of the Vps34 PI 3-kinase as a new potential drug target in insulin sensitization</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/M013278/1</gtr:grantReference><gtr:abstractText>This proposal aims to test the hypothesis that the Vps34 enzyme plays a role in metabolism. In our previous studies, using genetic approaches in the mouse and funded by the BBSRC, we have discovered that partial inactivation of Vps34 leads to improved glucose-tolerance and protection against the negative effects of a high fat diet. This suggests that Vps34 inhibitors could be useful in diseases such as diabetes. We now propose to test whether newly developed chemical blockers of Vps34 can induce the same effects as genetic inactivation of Vps34, in cell- and mouse-based models. This is a proof-of-concept project which, if the outcome is positive, can lay the foundations for Vps34 drug development and a translational programme of work.</gtr:abstractText><gtr:fund><gtr:end>2017-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2016-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>123215</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis Institutes for BioMedical Research (NIBR)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with Novartis Research Institution - Boston USA</gtr:description><gtr:id>281C2C8B-4528-4832-807A-2AE49AA3792F</gtr:id><gtr:impact>A manuscript describing the results of these studies is currently under review</gtr:impact><gtr:partnerContribution>Novartis provided a small molecule inhibitor against the vps34 Pi 3-kinase under MTA,</gtr:partnerContribution><gtr:piContribution>We have received a small molecule inhibitor from Novartis under MTA, and tested this compound to validate our genetic data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have discovered that inactivation of a PI 3-kinase enzyme (Vps34) at the organismal level leads to insulin sensitization and increased glucose tolerance. Using this award, we have shown that this occurs both upon genetic as well as pharmacological inactivation of this kinase.

Our study thus identifies Vps34 as a new drug target for the treatment of insulin resistance in Type 2 diabetes, conditions in which the unmet therapeutic need remains substantial.</gtr:description><gtr:exploitationPathways>Pharma might consider developing/using vps34 PI 3-kinase inhibitors as insulin sensitizers.</gtr:exploitationPathways><gtr:id>3FFD78E1-887A-4FDB-A48D-22E016CC957E</gtr:id><gtr:sectors><gtr:sector>Healthcare</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/M013278/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>